| A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge KR Edwards, H Malhi, K Schmidt, AR Davis, LJ Homad, NL Warner, ... npj Vaccines 9 (1), 120, 2024 | 1 | 2024 |
| N-cadherin dynamically regulates pediatric glioma cell migration in complex environments D Kim, JM Olson, JA Cooper The Journal of Cell Biology 223 (6), 2024 | | 2024 |
| MDB-86. ISOTRETINOIN HAS NO EFFECT ON EVENT FREE SURVIVAL ACROSS HIGH-RISK MEDULLOBLASTOMA MOLECULAR SUBGROUPS WHEN ADDED TO MAINTENANCE CHEMOTHERAPY: A SECONDARY ANALYSIS OF … SI Raskin, PMK de Blank, CA Billups, Y Li, JM Olson, SES Leary Neuro-Oncology 26 (Suppl 4), 0, 2024 | | 2024 |
| FBXO42 activity is required to prevent mitotic arrest, spindle assembly checkpoint activation and lethality in glioblastoma and other cancers P Hoellerbauer, M Kufeld, S Arora, K Mitchell, EJ Girard, JA Herman, ... NAR cancer 6 (2), zcae021, 2024 | | 2024 |
| Anti-mesothelin antigen-binding molecules and uses thereof C Correnti, A Bandaranayake, C Mehlin, JM Olson, S Meshinchi US Patent 11,987,640, 2024 | | 2024 |
| CYpHER: Catalytic extracellular targeted protein degradation with high potency and durable effect ZR Crook, GP Sevilla, P Young, EJ Girard, TD Phi, M Howard, J Price, ... bioRxiv, 2024 | | 2024 |
| Sensitive bispecific chimeric T cell receptors for cancer therapy S Simon, G Bugos, R Prins, A Rajan, A Palani, K Heyer, A Stevens, ... Research Square, 2024 | | 2024 |
| Versatile tissue‐injectable hydrogels capable of the extended hydrolytic release of bioactive protein therapeutics ES Nealy, SJ Reed, SM Adelmund, BA Badeau, JA Shadish, EJ Girard, ... Bioengineering & Translational Medicine, e10668, 2024 | | 2024 |
| Sex-specific differences in Yap1 and Cd276 function and expression regulate medulloblastoma progression and immune evasion N Abdelfattah, S Natarajan, HN Tran, J Maldonado, R McMinimy, ... Cancer Research 84 (6_Supplement), 3037-3037, 2024 | | 2024 |
| Epstein barr virus vaccines J Price, JM Olson, A McGuire, BL Stoddard US Patent App. 18/458,108, 2024 | | 2024 |
| Single-domain antibodies that bind ror1 J Price, CE Correnti, JM Olson US Patent App. 18/350,617, 2024 | | 2024 |
| Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks CA Jaeger-Ruckstuhl, Y Lo, E Fulton, OG Waltner, TB Shabaneh, S Simon, ... Immunity 57 (2), 287-302. e12, 2024 | 3 | 2024 |
| Preclinical pediatric brain tumor models for immunotherapy: Hurdles and a way forward DK Mishra, D Popovski, SM Morris, A Bondoc, S Senthil Kumar, EJ Girard, ... Neuro-oncology 26 (2), 226-235, 2024 | 1 | 2024 |
| Igm-multimerized single-domain antibodies that bind ror1 J Price, JM Olson US Patent App. 18/350,637, 2024 | | 2024 |
| Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity TB Shabaneh, AR Stevens, SM Stull, KR Shimp, BW Seaton, EA Gad, ... Journal for Immunotherapy of Cancer 12 (2), 2024 | 5 | 2024 |
| SARS-CoV-2 VACCINES AND USES THEREOF J Price, J Olson, CE Correnti, BL Stoddard US Patent App. 18/331,879, 2023 | | 2023 |
| Cartilage-homing peptides J Olson, AD Strand, EJ Girard, R Strong, C Mehlin, C Correnti, N Nairn US Patent App. 18/177,642, 2023 | | 2023 |
| SEX DIFFERENCES IN YAP1-CD276 EXPRESSION AND FUNCTION IN MEDULLOBLASTOMA IMMUNE EVASION N Abdelfattah, S Natarajan, J Madonado, H Borland, R McMinimy, S Chen, ... NEURO-ONCOLOGY 25, 2023 | | 2023 |
| Versatile Tissue-Injectable Hydrogels with Extended Hydrolytic Release of Bioactive Protein Therapeutics ES Nealy, SJ Reed, SM Adelmund, BA Badeau, JA Shadish, EJ Girard, ... bioRxiv, 2023 | | 2023 |
| Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma A Noll, C Myers, MC Biery, M Meechan, S Tahiri, A Rajendran, ME Berens, ... Neoplasia 43, 100921, 2023 | 1 | 2023 |
